MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Minesh Mehta

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	21
State	Published - Feb 14 2019

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{aef1ecd130694940a515353826c3fa34,

title = "MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges",

author = "Minesh Mehta",

note = "Neuro-Oncology (2019) 21(2):167-178",

year = "2019",

month = feb,

day = "14",

language = "American English",

volume = "21",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

AU - Mehta, Minesh

N1 - Neuro-Oncology (2019) 21(2):167-178

PY - 2019/2/14

Y1 - 2019/2/14

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/2925

M3 - Article

VL - 21

JO - Neuro-oncology

JF - Neuro-oncology

ER -

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Access to Document

Other files and links

Cite this